AHDC1

Across TCGA pan-cancer cohorts, AHDC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AHDC1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher AHDC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHDC1 expression acts as an unfavorable survival marker, although some lineages such as OV and CCRCC show a favorable association.

OV, CCRCC, and PDAC are the cancer types where AHDC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	1.000	0.812	.010	12	view →
CCRCC	DFS	Quartile	II,III,IV	0.733	0.323	.010	6	view →
PDAC	OS	Median	II,III,IV	0.393	0.594	.019	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AHDC1–OV (DFS)

Open the OV breakdown →